- Company
- Yuhan invests ₩23.1B in Yuhan USA over 4 years
- by Chon, Seung-Hyun Aug 18, 2022 05:48am
- Yuhan Corp is making aggressive investments in its US subsidiary. Investing &8361;23.1 billion during the past 4 years after establishing Yuhan USA in 2018, the company has been making broad steps to advance into the global market. According to the Financial Supervisory Service on the 17th, Yuhan Corp had invested &8361;7.7 billion in Yuhan
- Company
- Sanofi to supply flu vaccine Vaxigrip Tetra Nationwide
- by Aug 17, 2022 05:52am
- Sanofi's Korean subsidiary announced on the 16th that it has supplied its flu vaccine Vaxigrip Tetra nationwide on the 10th to mark this year's flu vaccination season. Sanofi supplied its flu vaccine earlier than usual so that those who need vaccinations can be vaccinated safely and effectively in preparation for the 2022-2023 seasonal flu
- Company
- Will the situation in the Atozet market improve?
- by Kim, Jin-Gu Aug 16, 2022 05:46am
- With the revision of guidelines for treating hyperlipidemia in Korea announced, attention is focused on how it will affect the prescription performance of major drugs. The pharmaceutical industry predicts that the Atorvastatin and Ezetimibe market, which has recently been growing rapidly, will benefit the most from the revision of the guideli
- Company
- Wakix, a new narcolepsy drug, can be prescribed at Big 5
- by Eo, Yun-Ho Aug 12, 2022 05:58am
- Wakix, a new narcolepsy drug, can be prescribed at the Big 5 General Hospital. According to the industry, it is Mitsubishi Tanabe Pharma's Wakix recently passed the DC of the Big 5, including Samsung Seoul Hospital, Seoul Asan Hospital, and Sinchon Severance Hospital. Wakix has been on the insurance benefit list since February, forming
- Company
- Verquvo for CHF, aims to enter insurance benefits
- by Eo, Yun-Ho Aug 11, 2022 06:03am
- Verquvo, a new drug for heart failure, aims to enter insurance benefits. dksl According to related industries, Bayer Korea has submitted an application for payment of Verquvo, a water-soluble guanylate cyclase (sGC) promoter that promotes the synthesis of intracellular cyclic Guanosine (cGMP). Verquvo was recently approved in December last ye
- Company
- AKLIEF can be prescribed at general hospitals
- by Eo, Yun-Ho Aug 10, 2022 05:53am
- According to related industries, Galderma Korea's AKLIEF passed the Drug Committee (DC) of higher general hospitals such as Samsung Medical Center and Sinchon Severance Hospital. AKLIEF is a retinoid-based treatment that has been recommended as the primary treatment for acne, and is evaluated as an innovative treatment that can simultaneou
- Company
- Gov improvement plan may reduce patient drug access
- by Eo, Yun-Ho Aug 10, 2022 05:53am
- The focus is on lowering the price of the drug rather than improving the registration, shortening the time and effectiveness are insignificant." "There was no discussion with the consultative body. It's hard to gather opinions from the industry." The KRPIA expressed strong opposition to the government's plan to strengthen access to new drugs.
- Company
- Baxter International’s GM Dong-Wook Hyun suddenly resigns
- by Eo, Yun-Ho Aug 9, 2022 05:56am
- Dong-Wook Hyun, General Manager of Baxter International Korea, resigned. According to industry sources, Hyun submitted his letter of resignation last month and left the company. The exact reason for his resignation remains unknown. With Hyun’s resignation, Baxter is now seeking a new head, during which Kwang-hyuk Im, Vice President of
- Company
- Korean companies win first round of Entresto patent suit
- by Kim, Jin-Gu Aug 8, 2022 06:09am
- The first patent dispute over Novartis’s heart failure treatment ‘Entresto (valsartan+ sacubitril) ended with the victory of the Korean generic companies. The exclusive market approval (first generic exclusivity) that received attention is expected to be granted to 10 companies including Hanmi Pharmaceuticals, with the possibility of D
- Company
- Revised guidelines for dyslipidemia in Korea
- by Eo, Yun-Ho Aug 8, 2022 06:09am
- In the management of dyslipidemia, it is believed that drug prescriptions will be more aggressive in Korea. In April, The Korean Society of Lipid and Atherosclerosis unveiled some of the contents of the fifth edition of the 2022 dyslipidemia treatment guidelines at the Spring Conference, and will officially announce it in September. What is n
